rivaroxaban and Aortitis

Rivaroxaban is a specific factor Xa (FXa) inhibitor for venous thromboembolism treatment. Recently, increasing evidence have reported the beneficial effects of rivaroxaban on treating cardiovascular disorders such as coronary and peripheral artery disease. However, its potential influence on abdominal aortic aneurysm (AAA) remains unclear. This study aims to investigate whether rivaroxaban treatment could attenuate experimental AAA progression and its related mechanisms.. Rivaroxaban attenuated both angiotensin II- and calcium chloride-induced abdominal aortic aneurysm (AAA) progressions, through inhibiting aortic remodeling and inflammation. Rivaroxaban could be a promising therapeutic agent in attenuating AAA development by counteracting FXa-induced aortic wall inflammation.

Topics: Angiotensin II; Animals; Anti-Inflammatory Agents; Aorta, Abdominal; Aortic Aneurysm, Abdominal; Aortitis; Calcium Chloride; Cell Adhesion Molecules; Cytokines; Dilatation, Pathologic; Disease Models, Animal; Disease Progression; Factor Xa Inhibitors; Humans; Inflammation Mediators; Male; Mice, Knockout, ApoE; Retrospective Studies; Rivaroxaban; Signal Transduction; Vascular Remodeling